Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:47:33.383Z.
Calculation as of: 2026-10-06T14:47:33.383Z.
Quote observation: 2026-10-06T14:44:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f3e61b787222715dff3a983a87307d60b14e7521dca9159fec0ee57fbd3bd529
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Lakewood-Amedex Biotherapeutics, Inc.
Market Cap
$1.46M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45M
EV/Sales Ratio
N/A
TTM Avg
0.01x
3Y Avg
35696307.79x
5Y Avg
35696307.79x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics, Inc. (LABT) | $1.46M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | 0.22x | 0.55x | 1.65x | 4.41x |
| PMGC Holdings Inc. (ELAB)vs › | $1.45M | N/A | 0.01x | 35696307.79x | 35696307.79x |
| Curis, Inc. (CRIS)vs › | $1.47M | N/A | 0.94x | 2.21x | 9.57x |
| NewcelX Ltd. (NCEL)vs › | $1.43M | N/A | N/A | N/A | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.41M | 0.69x | 1.00x | 2.40x | 3.38x |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.31M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | 0.33x | 0.51x | 0.45x | 1.23x |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | 21.72x | 279.56x | 279.56x | 279.56x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
